# OnCo record jong-mu-sun (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/jong-mu-sun/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "jong-mu-sun" ;
  schema:name "Jong-Mu Sun"@en ;
  schema:description "Korean oncologist who was lead author of KEYNOTE-590, the trial that added pembrolizumab to first-line chemotherapy for advanced oesophageal cancer."@en ;
  schema:url <https://onco.cc/people/jong-mu-sun/> ;
  schema:dateModified "2026-09-18"^^xsd:date ;
  onco:tag "oesophageal", "immunotherapy", "trialist" ;
  schema:jobTitle "Medical oncologist, Samsung Medical Center, Seoul" ;
  onco:cancers <https://onco.cc/cancers/oesophageal-squamous-cell-carcinoma/>, <https://onco.cc/cancers/oesophageal-adenocarcinoma/>, <https://onco.cc/cancers/esophageal/> ;
  onco:institutions <https://onco.cc/institutions/samsung-medical-center/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-keynote-590-lancet-2021/> ;
  schema:affiliation <https://onco.cc/institutions/samsung-medical-center/> .